Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab expanded companion diagnostic - Roche

Drug Profile

Atezolizumab expanded companion diagnostic - Roche

Alternative Names: PD-L1 rabbit monoclonal immunohistochemistry antibody assay; VENTANA PD-L1 (SP 263) Expanded Assay - Roche

Latest Information Update: 18 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Monoclonal antibody diagnostics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 24 Aug 2022 Launched for Non-small cell lung cancer (Diagnosis) in Iceland, Norway, Liechtenstein, European Union (unspecified route)
  • 23 Aug 2022 Registered for Non-small cell lung cancer (Diagnosis) in Liechtenstein, Norway, Iceland, European Union (unspecified route)
  • 23 Aug 2022 VENTANA PD-L1 (SP 263) Assay receives a CE label expansion as a companion diagnostic for atezolizumab (Tecentriq®) in non-small cell lung cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top